Volume 88 Issue 15 | p. 28 | Concentrates
Issue Date: April 12, 2010

Arsenic Binding Defeats Leukemia

Arsenic trioxide's efficacy comes from binding to a cysteine-rich region of a cancer protein, leading to protein degradation
Department: Science & Technology
Keywords: leukemia, arsenic, arsenic trioxide, zinc finger

Arsenic has been used for centuries as a medical treatment, and in the form of arsenic trioxide, it’s currently a highly effective FDA-approved treatment for a type of leukemia. Chinese researchers led by Sai-Juan Chen and Zhu Chen of Shanghai Jiao Tong University School of Medicine have now determined that As2O3 works by binding to a cysteine-rich region of a key protein found in promyelocytic leukemia patients, initiating a chain of events . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society